Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in Interest ReceivablesChange in Net LoansChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for iBio (IBIO) over the last 17 years, with Q4 2025 value amounting to $253000.0.

  • iBio's Share-based Compensation fell 4673.68% to $253000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $1.2 million, marking a year-over-year decrease of 2863.85%. This contributed to the annual value of $1.5 million for FY2025, which is 2492.64% down from last year.
  • Latest data reveals that iBio reported Share-based Compensation of $253000.0 as of Q4 2025, which was down 4673.68% from $323000.0 recorded in Q3 2025.
  • Over the past 5 years, iBio's Share-based Compensation peaked at $1.2 million during Q3 2022, and registered a low of $253000.0 during Q4 2025.
  • Its 5-year average for Share-based Compensation is $612500.0, with a median of $454000.0 in 2023.
  • Per our database at Business Quant, iBio's Share-based Compensation surged by 49365.08% in 2021 and then tumbled by 6826.05% in 2023.
  • iBio's Share-based Compensation (Quarter) stood at $960000.0 in 2021, then dropped by 4.69% to $915000.0 in 2022, then crashed by 50.38% to $454000.0 in 2023, then grew by 4.63% to $475000.0 in 2024, then crashed by 46.74% to $253000.0 in 2025.
  • Its Share-based Compensation stands at $253000.0 for Q4 2025, versus $323000.0 for Q3 2025 and $270000.0 for Q2 2025.